GT201700146A - Compuestos de triazolopirimidina y usos de los mismos - Google Patents
Compuestos de triazolopirimidina y usos de los mismosInfo
- Publication number
- GT201700146A GT201700146A GT201700146A GT201700146A GT201700146A GT 201700146 A GT201700146 A GT 201700146A GT 201700146 A GT201700146 A GT 201700146A GT 201700146 A GT201700146 A GT 201700146A GT 201700146 A GT201700146 A GT 201700146A
- Authority
- GT
- Guatemala
- Prior art keywords
- same
- triazolopirimidine
- compounds
- mediaated
- prc2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
SE PROPORCIONA UN COMPUESTO DE LA FÓRMULA (I), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, EL CUAL SE HA DEMOSTRADO ES ÚTIL PARA TRATAR UNA ENFERMEDAD O TRASTORNO MEDIADO POR PRC2: EN DONDE R1, R2, R3, R4, R5, Y N SON COMO SE DEFINEN EN LA PRESENTE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014094644 | 2014-12-23 | ||
CN2015095320 | 2015-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201700146A true GT201700146A (es) | 2019-06-12 |
Family
ID=55071101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201700146A GT201700146A (es) | 2014-12-23 | 2017-06-23 | Compuestos de triazolopirimidina y usos de los mismos |
Country Status (40)
Country | Link |
---|---|
US (5) | US9580437B2 (es) |
EP (1) | EP3237418B1 (es) |
JP (1) | JP6736559B2 (es) |
KR (1) | KR102534028B1 (es) |
CN (1) | CN107108637B (es) |
AU (1) | AU2015370524B2 (es) |
BR (1) | BR112017010354B8 (es) |
CA (1) | CA2969090C (es) |
CL (1) | CL2017001572A1 (es) |
CO (1) | CO2017005992A2 (es) |
CR (1) | CR20170285A (es) |
CY (1) | CY1121901T1 (es) |
DK (1) | DK3237418T3 (es) |
DO (1) | DOP2017000149A (es) |
EA (1) | EA032416B1 (es) |
EC (1) | ECSP17047153A (es) |
ES (1) | ES2722048T3 (es) |
GT (1) | GT201700146A (es) |
HR (1) | HRP20190805T1 (es) |
HU (1) | HUE043060T2 (es) |
IL (1) | IL252135B (es) |
JO (1) | JO3489B1 (es) |
LT (1) | LT3237418T (es) |
ME (1) | ME03385B (es) |
MX (1) | MX2017008529A (es) |
MY (1) | MY186837A (es) |
NZ (1) | NZ731664A (es) |
PE (1) | PE20171307A1 (es) |
PH (1) | PH12017501016A1 (es) |
PL (1) | PL3237418T3 (es) |
PT (1) | PT3237418T (es) |
RS (1) | RS58679B1 (es) |
SG (1) | SG11201703880VA (es) |
SI (1) | SI3237418T1 (es) |
SV (1) | SV2017005472A (es) |
TN (1) | TN2017000204A1 (es) |
TW (1) | TWI694076B (es) |
UA (1) | UA120945C2 (es) |
UY (1) | UY36462A (es) |
WO (1) | WO2016103155A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20170285A (es) * | 2014-12-23 | 2017-08-21 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos |
WO2017210395A1 (en) * | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
EP3472161B1 (en) | 2016-06-20 | 2020-03-25 | Novartis AG | Triazolopyridine compounds and uses thereof |
JP2019524872A (ja) * | 2016-06-20 | 2019-09-05 | ノバルティス アーゲー | 癌の治療に有用なイミダゾピリミジン化合物 |
BR112018076443A2 (pt) * | 2016-06-20 | 2019-04-09 | Novartis Ag | formas cristalinas de um composto de triazolopirimidina |
AU2017296289A1 (en) | 2016-07-12 | 2019-01-31 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors |
CN106831601A (zh) * | 2017-01-13 | 2017-06-13 | 河北博伦特药业有限公司 | 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法 |
MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
AU2018210770B2 (en) | 2017-01-23 | 2022-03-24 | Revolution Medicines, Inc. | Bicyclic compounds as allosteric SHP2 inhibitors |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
WO2018170290A1 (en) * | 2017-03-15 | 2018-09-20 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fmr1 expression |
US11312705B2 (en) * | 2017-03-16 | 2022-04-26 | Jiangsu Hengrui Medicine Co., Ltd. | Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof |
AU2018275123A1 (en) | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
WO2019062435A1 (zh) * | 2017-09-28 | 2019-04-04 | 中国科学院上海药物研究所 | 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病 |
CN109575013A (zh) * | 2017-09-28 | 2019-04-05 | 中国科学院上海药物研究所 | 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病 |
AU2018347516A1 (en) | 2017-10-12 | 2020-05-07 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
CN109867645B (zh) * | 2017-12-05 | 2021-09-14 | 中国医学科学院药物研究所 | 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法 |
CN111433205B (zh) * | 2017-12-15 | 2024-01-19 | 锐新医药公司 | 作为变构shp2抑制剂的多环化合物 |
CN109942556A (zh) * | 2017-12-21 | 2019-06-28 | 上海青煜医药科技有限公司 | 嘧啶酮化合物及其应用 |
CN111630042A (zh) | 2018-01-23 | 2020-09-04 | 巴斯夫欧洲公司 | 吡啶衍生物的卤化 |
AU2019214861B2 (en) | 2018-01-31 | 2021-11-18 | Mirati Therapeutics, Inc. | PRC2 inhibitors |
CN110156787B (zh) * | 2018-02-13 | 2021-11-02 | 中国科学院上海药物研究所 | 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途 |
CN110563722A (zh) * | 2018-06-06 | 2019-12-13 | 上海青煜医药科技有限公司 | 吡啶或哒嗪并环化合物及其应用 |
CN110734436A (zh) * | 2018-07-19 | 2020-01-31 | 上海青煜医药科技有限公司 | 嘧啶或吡嗪并环化合物及其应用 |
BR112021009880A2 (pt) * | 2018-11-30 | 2021-08-17 | Tuojie Biotech (Shanghai) Co., Ltd. | pirimidina e derivado de heterociclo de nitrogênio de cinco membros, método de preparação para os mesmos e usos médicos dos mesmos |
CN111518100A (zh) * | 2019-02-02 | 2020-08-11 | 上海青煜医药科技有限公司 | 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用 |
JP2022525199A (ja) * | 2019-03-15 | 2022-05-11 | フルクラム セラピューティクス,インコーポレイテッド | Eedおよびprc2調節物質としての大環状アゾロピリジン誘導体 |
JP7299307B2 (ja) * | 2019-04-03 | 2023-06-27 | テラ・ストーン株式会社 | チミン核酸塩基をベースとするトリアゾロピリミジン類及びその製造方法 |
JP2022530866A (ja) * | 2019-04-22 | 2022-07-04 | ミラティ セラピューティクス,インク. | Prc2阻害剤としてのナフチリジン誘導体 |
CN113874377A (zh) | 2019-05-13 | 2021-12-31 | 埃科莱布美国股份有限公司 | 作为铜腐蚀抑制剂的1,2,4-三唑并[1,5-a]嘧啶衍生物 |
KR20220027933A (ko) * | 2019-06-05 | 2022-03-08 | 미라티 테라퓨틱스, 인크. | 암을 치료하기 위한 prc2 억제제로서의 이미다조[1,2-c]피리미딘 유도체 |
CA3142477A1 (en) * | 2019-06-05 | 2020-12-10 | Athenex, Inc. | Methods of treating and/or preventing psoriasis |
WO2021032004A1 (zh) | 2019-08-22 | 2021-02-25 | 上海青煜医药科技有限公司 | 氮杂芳基化合物及其应用 |
CN114746414A (zh) * | 2019-09-26 | 2022-07-12 | 诺华公司 | 氮杂-喹啉化合物及其用途 |
EP4056570A4 (en) * | 2019-11-01 | 2023-12-20 | ShanghaiTech University | EED INHIBITOR AND PRODUCTION METHOD AND USE THEREOF |
CN113004233B (zh) * | 2019-12-18 | 2022-12-20 | 南京优氟医药科技有限公司 | 一种用于制备prc2抑制剂的化合物、其制备方法和用途 |
CN111333655B (zh) * | 2020-04-13 | 2021-07-13 | 武汉工程大学 | 一种三唑并嘧啶类化合物及其制备方法和应用 |
EP4149932A1 (en) * | 2020-05-11 | 2023-03-22 | Ascentage Pharma (Suzhou) Co., Ltd. | Preparation method of (5-fluoro-2, 3-dihydrobenzofuran-4-yl) methanamine or its salt, and intermediates thereof |
AU2021281123A1 (en) | 2020-05-28 | 2023-02-09 | Novartis Ag | Dosing regimens for N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-C]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof, for use in treating PRC2-mediated diseases or disorders |
CN114907385A (zh) | 2021-02-10 | 2022-08-16 | 上海青煜医药科技有限公司 | 氮杂芳基化合物、其制备方法及应用 |
WO2023016511A1 (zh) * | 2021-08-11 | 2023-02-16 | 上海青煜医药科技有限公司 | 氮杂芳基化合物、其制备方法及应用 |
CN117384153A (zh) * | 2022-07-12 | 2024-01-12 | 上海赛岚生物科技有限公司 | 一类甲基转移酶抑制剂及其用途 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
IL143236A0 (en) | 1998-12-16 | 2002-04-21 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
NL1014106C2 (nl) | 2000-01-18 | 2001-07-20 | Univ Amsterdam | Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit. |
CN1219753C (zh) | 2000-07-19 | 2005-09-21 | 沃尼尔·朗伯公司 | 4-碘苯氨基苯氧肟酸的氧合酯 |
SE519662C2 (sv) * | 2001-07-04 | 2003-03-25 | Asept Int Ab | Ventilanordning vid utportioneringsanordningar |
AU2002357667A1 (en) * | 2001-10-24 | 2003-05-06 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
US6921762B2 (en) * | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
MXPA04008722A (es) | 2002-03-08 | 2005-07-13 | Eisai Co Ltd | Compuestos macrociclicos utiles como farmaceuticos. |
PT3000810T (pt) | 2002-03-13 | 2017-10-25 | Array Biopharma Inc | Derivados de benzimidazole alquilado n3 como inibidores de mek |
GB0228900D0 (en) | 2002-12-11 | 2003-01-15 | Ml Lab Plc | Cancer Immunotherapy |
JP2004238296A (ja) | 2003-02-04 | 2004-08-26 | Kissei Pharmaceut Co Ltd | 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20060246505A1 (en) | 2003-09-02 | 2006-11-02 | Reinhard Walther | Modulation of the synthesis of insulin |
ATE449168T1 (de) | 2004-06-01 | 2009-12-15 | Univ North Carolina | Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
ES2481402T3 (es) | 2005-07-21 | 2014-07-30 | Ardea Biosciences, Inc. | Inhibidores de N-(arilamino)sulfonamida de MEK |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CA2648021A1 (en) | 2006-03-31 | 2007-10-11 | Ordway Research Institute, Inc. | Prognostic and diagnostic method for cancer therapy |
WO2008083251A2 (en) | 2006-12-27 | 2008-07-10 | Usc Stevens - University Of Southern California | Dna methylation markers based on epigenetic stem cell signatures in cancer |
WO2009017670A2 (en) | 2007-07-26 | 2009-02-05 | University Of Massachusetts | Ras-mediated epigenetic silencing effectors and uses thereof |
US8907091B2 (en) | 2007-08-29 | 2014-12-09 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
RU2523890C2 (ru) | 2007-09-12 | 2014-07-27 | Дженентек, Инк. | Комбинации ингибиторов фосфоинозитид 3-киназы и химиотерапевтических агентов и способы применения |
JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック, インコーポレイテッド | チエノピリミジン化合物の製造方法 |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
GB0822248D0 (en) | 2008-12-05 | 2009-01-14 | Medical Res Council | Crystal meths |
US8895526B2 (en) | 2009-03-27 | 2014-11-25 | Cold Spring Harbor Laboratory | Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers |
CN102020643A (zh) * | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
NZ603454A (en) * | 2010-05-07 | 2014-06-27 | Glaxosmithkline Llc | Indoles useful for treating cellular proliferation diseases such as cancer |
ES2570380T3 (es) | 2010-09-10 | 2016-05-18 | Epizyme Inc | Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento |
WO2012151277A1 (en) | 2011-05-02 | 2012-11-08 | Applied Informatic Solutions, Inc. | Kits and methods for selecting a treatment for ovarian cancer |
WO2013010181A2 (en) | 2011-07-14 | 2013-01-17 | University Of Massachusetts | Methods of diagnosing cancer using epigenetic biomarkers |
AU2012315566A1 (en) | 2011-09-30 | 2014-04-17 | Glaxosmithkline Llc | Methods of treating cancer |
WO2014124418A1 (en) | 2013-02-11 | 2014-08-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
AU2013232229B2 (en) | 2012-03-12 | 2017-11-23 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
WO2014078813A1 (en) | 2012-11-19 | 2014-05-22 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
US20150313906A1 (en) | 2012-12-19 | 2015-11-05 | Glaxosmithkline Llc | Combination |
EP2954056A4 (en) | 2013-02-08 | 2016-09-21 | Stemcentrx Inc | NEW MULTISPECIFIC CONSTRUCTIONS |
EP2968565A2 (en) | 2013-03-14 | 2016-01-20 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9776996B2 (en) * | 2013-03-15 | 2017-10-03 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
AU2015217152A1 (en) | 2014-02-11 | 2016-08-11 | Mitokinin, Inc. | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
UA123897C2 (uk) | 2014-11-14 | 2021-06-23 | Басф Се | Бензилпропаргілові прості ефіри як інгібітори нітрифікації |
ES2668688T3 (es) | 2014-12-16 | 2018-05-21 | Omya International Ag | Carbonato de calcio para protección vegetal |
CR20170285A (es) * | 2014-12-23 | 2017-08-21 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos |
MA41272A (fr) | 2014-12-23 | 2017-10-31 | Adama Makhteshim Ltd | 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
-
2015
- 2015-12-21 CR CR20170285A patent/CR20170285A/es unknown
- 2015-12-21 DK DK15820637.5T patent/DK3237418T3/da active
- 2015-12-21 HU HUE15820637A patent/HUE043060T2/hu unknown
- 2015-12-21 JP JP2017533767A patent/JP6736559B2/ja active Active
- 2015-12-21 CN CN201580070691.5A patent/CN107108637B/zh active Active
- 2015-12-21 WO PCT/IB2015/059843 patent/WO2016103155A1/en active Application Filing
- 2015-12-21 EP EP15820637.5A patent/EP3237418B1/en active Active
- 2015-12-21 CA CA2969090A patent/CA2969090C/en active Active
- 2015-12-21 PL PL15820637T patent/PL3237418T3/pl unknown
- 2015-12-21 AU AU2015370524A patent/AU2015370524B2/en active Active
- 2015-12-21 EA EA201791420A patent/EA032416B1/ru not_active IP Right Cessation
- 2015-12-21 SI SI201530725T patent/SI3237418T1/sl unknown
- 2015-12-21 SG SG11201703880VA patent/SG11201703880VA/en unknown
- 2015-12-21 UY UY0001036462A patent/UY36462A/es not_active Application Discontinuation
- 2015-12-21 US US14/977,273 patent/US9580437B2/en active Active
- 2015-12-21 NZ NZ731664A patent/NZ731664A/en unknown
- 2015-12-21 MY MYPI2017701623A patent/MY186837A/en unknown
- 2015-12-21 PE PE2017001154A patent/PE20171307A1/es unknown
- 2015-12-21 UA UAA201704770A patent/UA120945C2/uk unknown
- 2015-12-21 LT LTEP15820637.5T patent/LT3237418T/lt unknown
- 2015-12-21 RS RS20190502A patent/RS58679B1/sr unknown
- 2015-12-21 ES ES15820637T patent/ES2722048T3/es active Active
- 2015-12-21 PT PT15820637T patent/PT3237418T/pt unknown
- 2015-12-21 US US15/538,348 patent/US10220036B2/en active Active
- 2015-12-21 MX MX2017008529A patent/MX2017008529A/es active IP Right Grant
- 2015-12-21 BR BR112017010354A patent/BR112017010354B8/pt active IP Right Grant
- 2015-12-21 TN TN2017000204A patent/TN2017000204A1/en unknown
- 2015-12-21 KR KR1020177016880A patent/KR102534028B1/ko active IP Right Grant
- 2015-12-21 ME MEP-2019-127A patent/ME03385B/me unknown
- 2015-12-22 TW TW104143216A patent/TWI694076B/zh active
- 2015-12-22 JO JOP/2015/0331A patent/JO3489B1/ar active
-
2017
- 2017-05-07 IL IL252135A patent/IL252135B/en active IP Right Grant
- 2017-06-01 PH PH12017501016A patent/PH12017501016A1/en unknown
- 2017-06-16 CO CONC2017/0005992A patent/CO2017005992A2/es unknown
- 2017-06-16 CL CL2017001572A patent/CL2017001572A1/es unknown
- 2017-06-21 DO DO2017000149A patent/DOP2017000149A/es unknown
- 2017-06-23 GT GT201700146A patent/GT201700146A/es unknown
- 2017-06-23 SV SV2017005472A patent/SV2017005472A/es unknown
- 2017-07-20 EC ECIEPI201747153A patent/ECSP17047153A/es unknown
-
2019
- 2019-01-11 US US16/246,380 patent/US20190142837A1/en not_active Abandoned
- 2019-04-29 HR HRP20190805TT patent/HRP20190805T1/hr unknown
- 2019-04-30 CY CY20191100456T patent/CY1121901T1/el unknown
-
2020
- 2020-04-30 US US16/863,631 patent/US11207325B2/en active Active
-
2021
- 2021-10-19 US US17/505,271 patent/US11931363B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201700146A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
CO2017001884A2 (es) | Polimorfos de selinexor | |
DOP2018000257A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
GT201700033A (es) | Anticuerpos anti tigit | |
CL2019000844A1 (es) | Compuesto de piridina. | |
CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
EA201692219A1 (ru) | Способы получения противовирусных соединений | |
UY36702A (es) | Piridinas sustituidas y métodos de uso | |
CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
DOP2017000034A (es) | Compuestos de imidazopiridazina | |
CU20160003A7 (es) | Pirazololpiridinaminas sustituidas | |
UY35274A (es) | Compuestos y métodos para tratar infecciones bacterianas | |
BR112017009289A2 (pt) | métodos de administrar composições de amantadina | |
CR20160316A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
ECSP18003372A (es) | Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa | |
CL2019000487A1 (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana. | |
CR20150641U (es) | Composiciones farmacéuticas | |
AR120118A2 (es) | Anticuerpos anti tigit | |
GT201500232A (es) | Compuestos de azabencimidazol como inhibidores de las isozimas pde4 para el tratamiento de cns y otros trastornos | |
CL2015001705A1 (es) | Uso de pidotimod para tratar la psoriasis |